<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SULFATRIM- sulfamethoxazole and trimethoprim suspension </strong><br>STI Pharma LLC<br></p></div>
<h1>SULFATRIM<span class="Sup">TM</span> (Sulfamethoxazole and Trimethoprim Oral Suspension, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43cca713-654a-43ec-adb9-e732a10640e9"></a><a name="section-1"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim oral suspension and other antibacterial drugs, sulfamethoxazole and trimethoprim oral suspension should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_611382d2-f126-45eb-ab57-c67756e5705b"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sulfamethoxazole and trimethoprim is a synthetic antibacterial combination product containing 200 mg sulfamethoxazole and 40 mg trimethoprim per 5 mL for oral administration.</p>
<p>Sulfamethoxazole is <span class="Italics">N</span><span class="Sup">1</span>-(5-methyl-3-isoxazolyl)sulfanilamide; the molecular formula is C<span class="Sub">10</span>H<span class="Sub">11</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S. It is an almost white, odorless, tasteless compound with a molecular weight of 253.28 and the following structural formula is:</p>
<div class="Figure"><img alt="Sulfamethoxazole Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3ef596c8-689e-4349-a5dc-11645f8332ef&amp;name=b848770a-figure-01.jpg"></div>
<p>Trimethoprim is 2,4-diamino-5-(3,4,5- trimethoxybenzyl) pyrimidine; the molecular formula is C<span class="Sub">14</span>H<span class="Sub">18</span>N<span class="Sub">4</span>O<span class="Sub">3</span>. It is a white to light yellow, odorless, bitter compound with a molecular weight of 290.3 and. It has the following structural formula is:</p>
<div class="Figure"><img alt="Trimethoprim Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3ef596c8-689e-4349-a5dc-11645f8332ef&amp;name=b848770a-figure-02.jpg"></div>
<p><span class="Bold"></span><span class="Bold">INACTIVE INGREDIENTS: </span>alcohol (less than 0<span class="Bold">.</span>5%), carboxymethylcellulose sodium, citric acid, FD&amp;C Red #40, FD&amp;C Yellow #6, cherry flavor, methylparaben, microcrystalline cellulose and carboxymethylcellulose sodium, polysorbate 80, propylene glycol, propylparaben, purified water, saccharin sodium, simethicone emulsion, sucrose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_ca6218cd-2ffa-4a4e-9bb4-90172c265cd4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound, and metabolized forms; sulfamethoxazole also exists as the conjugated form. The metabolism of sulfamethoxazole occurs predominantly by N4-acetylation, although the glucuronide conjugate has been identified. The principal metabolites of trimethoprim are the 1- and 3-oxides and the 3’- and 4’-hydroxy derivatives. The free forms of sulfamethoxazole and trimethoprim are considered to be the therapeutically active forms. Approximately 70% of sulfamethoxazole and 44% of trimethoprim are bound to plasma proteins. The presence of 10 mg percent sulfamethoxazole in plasma decreases the protein binding of trimethoprim by an insignificant degree; trimethoprim does not influence the protein binding of sulfamethoxazole.</p>
<p>Peak blood levels for the individual components occur 1 to 4 hours after oral administration. The mean serum half-lives of sulfamethoxazole and trimethoprim are 10 and 8 to 10 hours, respectively. However, patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> exhibit an increase in the half-lives of both components, requiring dosage regimen adjustment (see <span class="Bold"><a href="#i4i_dosage_admin_id_64a68c49-9372-422c-ab0a-bb04ef9e09af">DOSAGE AND ADMINISTRATION</a></span> section). Detectable amounts of sulfamethoxazole and  trimethoprim are present in the blood 24 hours after drug administration. During administration of 800 mg sulfamethoxazole and 160 mg trimethoprim b.i.d., the mean steady-state plasma concentration of trimethoprim was 1.72 μg/mL. The steady-state mean plasma levels of free and total sulfamethoxazole were 57.4 μg/mL and 68.0 μg/mL, respectively. These steady-state levels were achieved after three days of drug administration.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">1</a>  Excretion of sulfamethoxazole and trimethoprim is primarily by the kidneys through both glomerular filtration and tubular secretion. Urine concentrations of both sulfamethoxazole and trimethoprim are considerably higher than are the concentrations in the blood. The average percentage of the dose recovered in urine from 0 to 72 hours after a single oral dose of sulfamethoxazole and trimethoprim is 84.5% for total sulfonamide and 66.8% for free trimethoprim. Thirty percent of the total sulfonamide is excreted as free sulfamethoxazole, with the remaining as N<span class="Sub">4</span>-acetylated metabolite.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">2</a> When administered together as sulfamethoxazole and trimethoprim, neither sulfamethoxazole nor trimethoprim affects the urinary excretion pattern of the other.</p>
<p>Both sulfamethoxazole and trimethoprim distribute to <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, vaginal fluid and middle ear fluid; trimethoprim also distributes to bronchial secretions, and both pass the placental barrier and are excreted in human milk.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3e67e291-4822-4362-8bae-60a901cac65a"></a><a name="section-3.1"></a><p></p>
<h2>Geriatric Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of sulfamethoxazole 800 mg and trimethoprim 160 mg were studied in 6 geriatric subjects (mean age: 78.6 years) and 6 young healthy subjects (mean age: 29.3 years) using a non-U.S. approved formulation. Pharmacokinetic values for sulfamethoxazole in geriatric subjects were similar to those observed in young adult subjects. The mean renal clearance of trimethoprim was significantly lowered in geriatric subjects compared with young adult subjects (19 mL/h/kg vs. 55 mL/h/kg). However, after normalizing by body weight, the apparent total body clearance of trimethoprim was an average 19% lower in geriatric subjects compared with young adult subjects.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">3</a></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_47ef5d10-294b-4656-ae3d-438670d9b573"></a><a name="section-3.2"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. Thus, sulfamethoxazole and trimethoprim blocks two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria.</p>
<p><span class="Italics">In vitro</span> studies have shown that <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">bacterial resistance</span> develops more slowly with both sulfamethoxazole trimethoprim in combination than with either sulfamethoxazole or trimethoprim alone.</p>
<p>Sulfamethoxazole and trimethoprim have been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#i4i_indications_id_2ecbf538-3cb7-4664-96a7-9734a19b67aa">INDICATIONS AND USAGE</a></span> section.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7fc69679-b33a-4268-8764-169194852e2c"></a><a name="section-3.2.1"></a><p></p>
<h3>Aerobic gram-positive microorganisms:</h3>
<p class="First"><span class="Italics">Streptococcus pneumoniae</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43d8e359-4811-4456-8479-d1c09ad5dd81"></a><a name="section-3.2.2"></a><p></p>
<h3>Aerobic gram-negative microorganisms: </h3>
<p class="First">Escherichia coli (including susceptible enterotoxigenic <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> implicated in traveler's <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>)</p>
<p><span class="Italics">Klebsiella </span>species</p>
<p><span class="Italics">Enterobacter </span>species</p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p><span class="Italics">Morganella morganii</span></p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Italics">Proteus vulgaris</span></p>
<p><span class="Italics">Shigella flexneri</span></p>
<p><span class="Italics">Shigella sonnei</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ee9c0c62-81c6-4b7a-84c7-a1923e6a522c"></a><a name="section-3.2.3"></a><p></p>
<h3>Other Organisms:</h3>
<p class="First"><span class="Italics">Pneumocystis carinii</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f68c6208-c6a0-4341-97e5-e9953d873f0e"></a><a name="section-3.2.4"></a><p></p>
<h3>Susceptibility Testing Methods:</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_396caacb-c537-467b-b9b9-b445f9a27a27"></a><a name="section-3.2.4.1"></a><p></p>
<h4>Dilution Techniques:</h4>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">4</a> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of sulfamethoxazole/trimethoprim powder. The MIC values should be interpreted according to the following criteria:  </p>
<p>For testing Enterobacteriaceae:</p>
<a name="id_5c023d05-ac90-4827-97fe-747e18bd72ea"></a><table border="none" width="185">
<col width="51.6%">
<col width="48.6%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">MIC (μg/mL)</td>
<td align="left" valign="top">Interpretation</td>
</tr>
<tr>
<td align="left" valign="top">≤ 2/38</td>
<td align="left" valign="top">Susceptible (S)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">≥ 4/76</td>
<td align="left" valign="top">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>When testing either Haemophilus influenzae<span class="Sup">a</span> or Streptococcus pneumoniae<span class="Sup">b</span>:</p>
<a name="id_94be165d-af43-4ebc-a643-dc1a69fbdbbf"></a><table border="none" width="185">
<col width="51.6%">
<col width="48.6%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">MIC (μg/mL)</td>
<td align="left" valign="top">Interpretation<span class="Sup">b</span>
</td>
</tr>
<tr>
<td align="left" valign="top">≤ 0.5/9.5</td>
<td align="left" valign="top">Susceptible (S)</td>
</tr>
<tr>
<td align="left" valign="top">1/19 – 2/38</td>
<td align="left" valign="top">Intermediate (I)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">≥ 4/76</td>
<td align="left" valign="top">Resistant (R)</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a.</span>These interpretative standards are applicable only to broth microdilution susceptibility tests with <span class="Italics">Haemophilus influenzae</span> using <span class="Italics">Haemophilus</span> Test Medium (HTM).<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">4</a></p>
<p><span class="Sup">b.</span>These interpretative standards are applicable only to broth microdilution susceptibility tests using cation-adjusted Mueller-Hinton broth with 2% to 5% lysed horse blood.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">4 </a></p>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57612a95-c6f6-44a0-aed9-f300799657f8"></a><a name="section-3.2.5"></a><p></p>
<h3>Quality Control</h3>
<p class="First">Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard sulfamethoxazole/trimethoprim powder should provide the following range of values:  </p>
<a name="id_f763e58a-6fd5-47cc-abaa-13fb7c168044"></a><table border="none" width="443">
<col width="33.3%">
<col width="33.3%">
<col width="33.3%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Microorganism</td>
<td class="Toprule" align="left" valign="top"></td>
<td align="left" valign="top">MIC (μg/mL)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Escherichia coli</span></td>
<td align="left" valign="top">ATCC 25922</td>
<td align="left" valign="top">≤ 0.5/9.5</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Haemophilus influenzae</span><span class="Sup">c</span>
</td>
<td align="left" valign="top">ATCC 49247</td>
<td align="left" valign="top">0.03/0.59 – 0.25/4.75</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">
<span class="Italics">Streptococcus pneumoniae</span><span class="Sup">d</span>
</td>
<td align="left" valign="top">ATCC 49619</td>
<td align="left" valign="top">0.12/2.4 – 1/19</td>
</tr>
</tbody>
</table>
<p><span class="Sup">c.</span>This quality control range is applicable only to <span class="Italics">Haemophilus influenzae</span> ATCC 49247 tested by broth microdilution procedure using <span class="Italics">Haemophilus </span>Test Medium (HTM).<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">4</a></p>
<p><span class="Sup">d.</span>This quality control range is applicable to tests performed by the broth microdilution method only using cation-adjusted Mueller-Hinton broth with 2% to 5% lysed horse blood.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">4</a></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd3b7845-5bd5-40e3-98aa-3bdfbf6c92b3"></a><a name="section-3.2.5.1"></a><p></p>
<h4>Diffusion Techniques:</h4>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure5 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 1.25/23.75 μg of sulfamethoxazole/trimethoprim to test the susceptibility of microorganisms to sulfamethoxazole/trimethoprim.  </p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 1.25/23.75 mcg of sulfamethoxazole/trimethoprim disk should be interpreted according to the following criteria: </p>
<p>For testing either Enterobacteriaceae or Haemophilus influenzae<span class="Sup">e</span>:</p>
<a name="id_f8a4beb7-ad90-4133-b944-ca5eff973305"></a><table border="none" width="230">
<col width="57.1%">
<col width="43.0%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Zone Diameter (mm)</td>
<td align="left" valign="top">Interpretation</td>
</tr>
<tr>
<td align="left" valign="top">≥ 16</td>
<td align="left" valign="top">Susceptible (S)</td>
</tr>
<tr>
<td align="left" valign="top">11 – 15</td>
<td align="left" valign="top">Intermediate (I)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">≤ 10</td>
<td align="left" valign="top">Resistant (R)</td>
</tr>
</tbody>
</table>
<p><span class="Sup">e.</span>These zone diameter standards are applicable only for disk diffusion testing with Haemophilus influenzae and Haemophilus Test Medium (HTM).<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">5 </a></p>
<p>When testing Streptococcus pneumoniae<span class="Sup">f</span>:</p>
<a name="id_42b6d28c-a53c-42aa-8fac-2433176acabb"></a><table border="none" width="239">
<col width="62.5%">
<col width="37.7%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Zone Diameter (mm)</td>
<td align="left" valign="top">Interpretation</td>
</tr>
<tr>
<td align="left" valign="top">≥ 19</td>
<td align="left" valign="top">Susceptible (S)</td>
</tr>
<tr>
<td align="left" valign="top">16 – 18</td>
<td align="left" valign="top">Intermediate (I)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">≤ 15</td>
<td align="left" valign="top">Resistant (R)</td>
</tr>
</tbody>
</table>
<p><span class="Sup">f. </span>These zone diameter interpretative standards are applicable only to tests performed using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood when incubated in 5% CO2.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">5 </a></p>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for sulfamethoxazole/trimethoprim.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cab7fd98-e126-4687-8dbb-86ef3c38f95c"></a><a name="section-3.2.6"></a><p></p>
<h3>Quality Control</h3>
<p class="First">As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 1.25/23.75 μg sulfamethoxazole/trimethoprim disk* should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>: </p>
<a name="id_5d63036f-3cb7-4c44-84c7-583c87990783"></a><table border="single" width="476">
<col width="34.7%">
<col width="22.7%">
<col width="42.6%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" align="left" valign="middle">Microorganism</td>
<td class="Toprule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle">Zone Diameter Range (mm)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle"><span class="Italics">Escherichia coli </span></td>
<td align="center" valign="middle">ATCC 25922 </td>
<td class="Rrule" align="center" valign="middle">23–29 </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="middle">
<span class="Italics">Haemophilus influenzae</span>g </td>
<td align="center" valign="middle">ATCC 49247 </td>
<td class="Rrule" align="center" valign="middle">24–32 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="middle">
<span class="Italics">Streptococcus pneumoniae</span>h </td>
<td class="Botrule" align="center" valign="middle">ATCC 49619 </td>
<td class="Botrule Rrule" align="center" valign="middle">20–28 </td>
</tr>
</tbody>
</table>
<p>* Mueller-Hinton agar should be checked for excessive levels of thymidine or thymine. To determine whether Mueller-Hinton medium has sufficiently low levels of thymidine and thymine, an <span class="Italics">Enterococcus faecalis </span>(ATCC 29212 or ATCC 33186) may be tested with sulfamethoxazole/trimethoprim disks. A zone of inhibition ≥20 mm that is essentially free of fine colonies indicates a sufficiently low level of thymidine and thymine. </p>
<p><span class="Sup">g.</span>This quality control range is applicable only to Haemophilus influenzae ATCC 49247 tested by a disk diffusion procedure using Haemophilus Test Medium (HTM).<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">5</a></p>
<p><span class="Sup"> h.</span>This quality control range is applicable only to tests performed by disk diffusion using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood when incubated in 5% CO2.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">5</a></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_2ecbf538-3cb7-4664-96a7-9734a19b67aa"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim oral suspension and other antibacterial drugs, sulfamethoxazole and trimethoprim oral suspension should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a6335bc-a334-4c5e-a6ad-41f4a9f71b0d"></a><a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></h2>
<p class="First">For the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms: <span class="Italics">Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis </span>and <span class="Italics">Proteus vulgaris</span>. It is recommended that initial episodes of uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> be treated with a single effective antibacterial agent rather than the combination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d827c54c-1e4e-46a3-848d-a3570a3cc39c"></a><a name="section-4.2"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></h2>
<p class="First">For the treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> in pediatric patients due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pneumoniae </span>or <span class="Italics">Haemophilus influenzae</span> when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim is not indicated for <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> or prolonged administration in <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> at any age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a8d07db3-2a17-4166-8531-64ea4ae8a490"></a><a name="section-4.3"></a><p></p>
<h2>Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> in Adults</h2>
<p class="First">For the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pneumoniae </span>or <span class="Italics">Haemophilus influenzae</span> when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of a single antimicrobial agent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_befa6342-8d2f-4275-9875-7dcd3e5d099b"></a><a name="section-4.4"></a><p></p>
<h2>Shigellosis</h2>
<p class="First">For the treatment of <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Shigella flexneri </span>and <span class="Italics">Shigella sonnei</span> when antibacterial therapy is indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_65318cae-1cd4-4786-9de4-bae396cd5763"></a><a name="section-4.5"></a><p></p>
<h2>
<span class="Italics">P</span>neumocystis <span class="Italics">Carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></h2>
<p class="First">For the treatment of documented <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and for prophylaxis against <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in individuals who are immunosuppressed and considered to be at an increased risk of developing <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4edbd2c6-b608-4f78-8094-6740bc7cb1c1"></a><a name="section-4.6"></a><p></p>
<h2>Travelers' <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> in Adults</h2>
<p class="First">For the treatment of travelers' <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterotoxigenic E. coli.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_a957e3ed-b8e2-4136-a713-933c32fa557d"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Sulfamethoxazole and trimethoprim is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to trimethoprim or sulfonamides, in patients with a history of drug-induced immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with use of trimethoprim and/or sulfonamides, and in patients with documented <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> due to <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>. Sulfamethoxazole and trimethoprim is also contraindicated in pregnant patients and nursing mothers, because sulfonamides pass the placenta and are excreted in the milk and may cause <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>. Sulfamethoxazole and trimethoprim oral suspension is contraindicated in pediatric patients less than 2 months of age. Sulfamethoxazole and trimethoprim is also contraindicated in patients with marked <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatic damage</span> or with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> when renal function status cannot be monitored.  </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_38a50f0c-09fe-4f1a-afa3-359fefa6c273"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">STEVENS-JOHNSON SYNDROME</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">TOXIC EPIDERMAL NECROLYSIS</span>, FULMINANT <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">HEPATIC NECROSIS</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">APLASTIC ANEMIA</span> AND OTHER <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">BLOOD DYSCRASIAS</span>.</span></p>
<p><span class="Bold">SULFONAMIDES, INCLUDING SULFONAMIDE-CONTAINING PRODUCTS SUCH AS SULFAMETHOXAZOLE/TRIMETHOPRIM, SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">SKIN RASH</span> OR ANY SIGN OF ADVERSE REACTION.</span> In rare instances, a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> may be followed by a more severe reaction, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and serious <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span> (see <span class="Bold"><a href="#i4i_precautions_id_7f1a111c-2d6a-42d9-8678-750270f9f556">PRECAUTIONS</a></span>).  Clinical signs, such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> may be early indications of serious reactions.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and pulmonary infiltrates are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> of the respiratory tract that have been reported in association with sulfonamide treatment.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7c57d3ff-5208-4bd0-8246-79382e5f69fc"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></h2>
<p class="First">Sulfamethoxazole/trimethoprim-induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> may be an immune-mediated disorder. Severe cases of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> that are fatal or life threatening have been reported. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> usually resolves within a week upon discontinuation of sulfamethoxazole/trimethoprim. </p>
<p>The sulfonamides should not be used for the treatment of group A β-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>. In an established <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, they will not eradicate the streptococcus and, therefore, will not prevent sequelae such as <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>.</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including sulfamethoxazole and trimethoprim and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antiobiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_7f1a111c-2d6a-42d9-8678-750270f9f556"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_7cf621a1-17b6-4f4a-ac16-e11a3bb0fae1"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing sulfamethoxazole and trimethoprim in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Sulfamethoxazole and trimethoprim oral suspension should be given with caution to patients with impaired renal or hepatic function, to those with possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span> (e.g., the elderly, chronic alcoholics, patients receiving anticonvulsant therapy, patients with <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndrome</span>, and patients in <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span> states) and to those with severe allergies or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. In glucose-6-phosphate dehydrogenase deficient individuals, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> may occur. This reaction is frequently dose-related (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_ca6218cd-2ffa-4a4e-9bb4-90172c265cd4">CLINICAL PHARMACOLOGY</a></span>and <span class="Bold"><a href="#i4i_dosage_admin_id_64a68c49-9372-422c-ab0a-bb04ef9e09af">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_788b00f2-1a00-437e-921d-c1d4ab3e7aaf"></a><a name="section-7.2"></a><p></p>
<h2>Use in the Elderly</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in non-diabetic patients treated with sulfamethoxazole and trimethoprim are seen rarely, usually occurring after a few days of therapy. Patients with renal dysfunction, liver disease, <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span> or those receiving high doses of sulfamethoxazole and trimethoprim are particularly at risk.</p>
<p>Hematological changes indicative of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span> may occur in elderly patients or in patients with preexisting <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span> or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>. These effects are reversible by folinic acid therapy.</p>
<p>Trimethoprim has been noted to impair phenylalanine metabolism, but this is of no significance in phenylketonuric patients on appropriate dietary restriction.</p>
<p>As with all drugs containing sulfonamides, caution is advisable in patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> or thyroid dysfunction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e075e37c-c00e-4ce7-9e4a-23a8bf0e0754"></a><a name="section-7.3"></a><p></p>
<h2>Use in the Treatment of and Prophylaxis for <span class="Italics">Pneumocystis Carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> in Patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immunodeficiency Syndrome</span> (AIDS)</h2>
<p class="First">AIDS patients may not tolerate or respond to sulfamethoxazole and trimethoprim in the same manner as non-AIDS patients. The incidence of side effects, particularly <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and elevated aminotransferase (transaminase) values, with sulfamethoxazole and trimethoprim therapy in AIDS patients who are being treated for <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> has been reported to be greatly increased compared with the incidence normally associated with the use of sulfamethoxazole and trimethoprim in non-AIDS patients. The incidence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> appears to be increased in AIDS patients receiving sulfamethoxazole and trimethoprim. Adverse effects are generally less severe in patients receiving sulfamethoxazole and trimethoprim for prophylaxis. A history of mild intolerance to sulfamethoxazole and trimethoprim oral suspension in AIDS patients does not appear to predict intolerance of subsequent secondary prophylaxis.6 However, if a patient develops <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any sign of adverse reaction, therapy with sulfamethoxazole and trimethoprim should be reevaluated (see <span class="Bold"><a href="#i4i_warnings_id_38a50f0c-09fe-4f1a-afa3-359fefa6c273">WARNINGS</a></span>). </p>
<p>High dosage of trimethoprim, as used in patients with <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, induces a progressive but reversible increase of serum potassium concentrations in a substantial number of patients. Even treatment with recommended doses may cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> when trimethoprim is administered to patients with underlying disorders of potassium metabolism, with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, or if drugs known to induce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> are given concomitantly. Close monitoring of serum potassium is warranted in these patients. </p>
<p>During treatment, adequate fluid intake and urinary output should be ensured to prevent <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>. Patients who are "slow acetylators" may be more prone to idiosyncratic reactions to sulfonamides.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_aed48c7c-3254-4b95-b20f-a4822184e7ea"></a><a name="section-7.4"></a><p></p>
<h2>Information for patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including sulfamethoxazole and trimethoprim oral suspension should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When sulfamethoxazole and trimethoprim oral suspension is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by sulfamethoxazole and trimethoprim oral suspension or other antibaceterial drugs in the future.</p>
<p>Patients should be instructed to maintain an adequate fluid intake in order to prevent <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> and stone formation.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with and without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_4edd13cb-a48b-47e5-9f45-d93105e5dce4"></a><a name="section-7.5"></a><p></p>
<h2>Laboratory tests</h2>
<p class="First">Complete blood counts should be done frequently in patients receiving sulfamethoxazole and trimethoprim; if a significant reduction in the count of any formed blood element is noted, sulfamethoxazole and trimethoprim should be discontinued. Urinalyses with careful microscopic examination and renal function tests should be performed during therapy, particularly for those patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_02884bd2-3bf3-463c-9c0f-474ca663caa8"></a><a name="section-7.6"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> has been reported. </p>
<p>It has been reported that sulfamethoxazole and trimethoprim may prolong the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients who are receiving the anticoagulant warfarin. This interaction should be kept in mind when sulfamethoxazole and trimethoprim is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed.</p>
<p>Sulfamethoxazole and trimethoprim may inhibit the hepatic metabolism of phenytoin. Sulfamethoxazole and trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.</p>
<p>Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations.</p>
<p>There have been reports of marked but reversible <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> with coadministration of sulfamethoxazole and trimethoprim and cyclosporine in renal transplant recipients. </p>
<p>Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored. Increased sulfamethoxazole blood levels may occur in patients who are also receiving indomethacin. </p>
<p>Occasional reports suggest that patients receiving pyrimethamine as <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis in doses exceeding 25 mg weekly may develop <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> if sulfamethoxazole and trimethoprim is prescribed. </p>
<p>The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. </p>
<p>Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. </p>
<p>In the literature, a single case of toxic <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> has been reported after concomitant intake of sulfamethoxazole/trimethoprim and amantadine.</p>
<p>In the literature, three cases of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in elderly patients have been reported after concomitant intake of sulfamethoxazole/trimethoprim and an angiotensin converting enzyme inhibitor.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">7,8</a></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_723992af-631a-45b0-803b-f857b5d89bcd"></a><a name="section-7.7"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Sulfamethoxazole and trimethoprim, specifically the trimethoprim component, can interfere with a serum methotrexate assay as determined by the competitive binding protein technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA).</p>
<p>The presence of sulfamethoxazole and trimethoprim may also interfere with the Jaffé alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_74e78c13-14f4-4f45-8829-9a3773d0ed52"></a><a name="section-7.8"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f156bddf-88d6-4b1a-8b56-05db1eb56484"></a><a name="section-7.8.1"></a><p></p>
<h3>Carcinogenesis</h3>
<p class="First">Long-term studies in animals to evaluate carcinogenic potential have not been conducted with sulfamethoxazole and trimethoprim.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3ea328d-aec3-4e61-b039-461806390a85"></a><a name="section-7.8.2"></a><p></p>
<h3>Mutagenesis</h3>
<p class="First">Bacterial mutagenic studies have not been performed with sulfamethoxazole and trimethoprim in combination. Trimethoprim was demonstrated to be nonmutagenic in the Ames assay.  No chromosomal damage was observed in human leukocytes cultured <span class="Italics">in vitro </span>with sulfamethoxazole and trimethoprim alone or in combination; the concentrations used exceeded blood levels of these compounds following therapy with sulfamethoxazole and trimethoprim. Observations of leukocytes obtained from patients treated with sulfamethoxazole and trimethoprim revealed no chromosomal abnormalities. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_be8cb072-4a2c-4c23-88c1-deab684f8e5d"></a><a name="section-7.8.3"></a><p></p>
<h3>Impairment of Fertility</h3>
<p class="First">No adverse effects on fertility or general reproductive performance were observed in rats given oral dosages as high as 350 mg/kg/day sulfamethoxazole plus 70 mg/kg/day trimethoprim.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_8c5cc9fb-b550-476b-874d-898ec7a2f765"></a><a name="section-7.9"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_8dbdb93d-ad50-47a7-af74-bdfba310ad73"></a><a name="section-7.9.1"></a><p></p>
<h3>Teratogenic effects</h3>
<p class="First">Pregnancy Category C. In rats, oral doses of 533 mg/kg or 200 mg/kg produced teratologic effects manifested mainly as <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span>.</p>
<p>The highest dose which did not cause <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> in rats was 512 mg/kg sulfamethoxazole or 192 mg/kg trimethoprim when administered separately. In two studies in rats, no teratology was observed when 512 mg/kg of sulfamethoxazole was used in combination with 128 mg/kg of trimethoprim. In one study, however, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> were observed in one litter out of 9 when 355 mg/kg of sulfamethoxazole was used in combination with 88 mg/kg of trimethoprim.</p>
<p>In some rabbit studies, an overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with doses of trimethoprim 6 times the human therapeutic dose.</p>
<p>While there are no large, well-controlled studies on the use of sulfamethoxazole and trimethoprim in pregnant women, Brumfitt and Pursell,<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">9</a> in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or sulfamethoxazole and trimethoprim. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving sulfamethoxazole and trimethoprim. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral sulfamethoxazole and trimethoprim at the time of conception or shortly thereafter.</p>
<p>Because sulfamethoxazole and trimethoprim may interfere with folic acid metabolism, sulfamethoxazole and trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_76e3e123-d504-4589-a682-33fb57476917"></a><a name="section-7.9.2"></a><p></p>
<h3>Nonteratogenic effects</h3>
<p class="First">See <span class="Bold"><a href="#i4i_contraindications_id_a957e3ed-b8e2-4136-a713-933c32fa557d">CONTRAINDICATIONS</a></span> section.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0e72fefb-52f1-4bda-8aab-0edb192a3289"></a><a name="section-7.10"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">See <span class="Bold"><a href="#i4i_contraindications_id_a957e3ed-b8e2-4136-a713-933c32fa557d">CONTRAINDICATIONS</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_c6aad20e-0d69-43e4-8cbe-b5844ed10a5d"></a><a name="section-7.11"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Sulfamethoxazole and trimethoprim is not recommended for infants younger than 2 months of age (see <span class="Bold"><a href="#i4i_indications_id_2ecbf538-3cb7-4664-96a7-9734a19b67aa">INDICATIONS AND USAGE</a></span> and <span class="Bold"><a href="#i4i_contraindications_id_a957e3ed-b8e2-4136-a713-933c32fa557d">CONTRAINDICATIONS</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_e0c6a7d6-3121-42bf-8457-15b8ed5f7bf1"></a><a name="section-7.12"></a><p></p>
<h2>Geriatric use</h2>
<p class="First">Clinical studies of sulfamethoxazole and trimethoprim did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
<p>There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>, or concomitant use of other drugs. Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, generalized bone marrow suppression (see <span class="Bold"><a href="#i4i_warnings_id_38a50f0c-09fe-4f1a-afa3-359fefa6c273">WARNINGS</a></span>and <span class="Bold"><a href="#i4i_adverse_effects_id_fa7f818b-8d0b-4e2f-a838-027323f26056">ADVERSE REACTIONS </a></span> sections), a specific decrease in platelets (with or without <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>), and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased incidence of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> has been reported. Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span> may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions (see <span class="Bold"><a href="#i4i_dosage_admin_id_64a68c49-9372-422c-ab0a-bb04ef9e09af">DOSAGE AND ADMINISTRATION</a></span> sections). The trimethoprim component of sulfamethoxazole and trimethoprim may cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> when administered to patients with underlying disorders of potassium metabolism, with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or when given concomitantly with drugs known to induce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of sulfamethoxazole and trimethoprim treatment is recommended to help lower potassium serum levels.</p>
<p>Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher and mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects  (see <span class="Bold"><a href="#i4i_section_id_3e67e291-4822-4362-8bae-60a901cac65a">CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_fa7f818b-8d0b-4e2f-a838-027323f26056"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS </h1>
<p class="First">The most common adverse effects are <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) and <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span> (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>). <span class="Bold">FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">STEVENS-JOHNSON SYNDROME</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">TOXIC EPIDERMAL NECROLYSIS</span>, FULMINANT <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">HEPATIC NECROSIS</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">APLASTIC ANEMIA</span> AND OTHER <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">BLOOD DYSCRASIAS</span> (SEE <a href="#i4i_warnings_id_38a50f0c-09fe-4f1a-afa3-359fefa6c273">WARNINGS </a> SECTION).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_778e2446-e76e-45c3-ac02-da4602e398e0"></a><a name="section-8.1"></a><p></p>
<h2>Hematologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>, <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba5c9d81-6c01-41d4-aef8-54f6da402677"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, allergic <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, Henoch-Schönlein <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like syndrome, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, conjunctival and scleral injection, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In addition, <span class="product-label-link" type="condition" conceptid="320749" conceptname="Polyarteritis nodosa">periarteritis nodosa</span> and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3da2ce72-85f3-472a-bae5-0198ba8ee06f"></a><a name="section-8.3"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> (including <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>) elevation of serum transaminase and bilirubin, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_768f302a-22ee-48d3-8ce9-73361735814d"></a><a name="section-8.4"></a><p></p>
<h2>Genitourinary</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, BUN and serum creatinine elevation, toxic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> in association with cyclosporine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e75c826-2cdf-4904-a65c-b82c15266d11"></a><a name="section-8.5"></a><p></p>
<h2>Metabolic and Nutritional</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> (see <span class="Bold"><span class="Italics"><a href="#i4i_section_id_e075e37c-c00e-4ce7-9e4a-23a8bf0e0754">PRECAUTIONS: Use in the Treatment of and Prophylaxis for <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis Carinii Pneumonia</span> in Patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immunodeficiency Syndrome</span> (AIDS)</a></span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f70f3980-f88b-49cf-b630-7860d7deeca5"></a><a name="section-8.6"></a><p></p>
<h2>Neurologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bfc48ccb-358d-4257-89de-55fadc4d981e"></a><a name="section-8.7"></a><p></p>
<h2>Psychiatric</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_502856e2-f11b-425b-9e40-1db7674d9897"></a><a name="section-8.8"></a><p></p>
<h2>Endocrine</h2>
<p class="First">The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides) and oral hypoglycemic agents. Cross-sensitivity may exist with these agents. <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Diuresis</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> have occurred rarely in patients receiving sulfonamides.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e138fe5e-ece8-4aff-8a81-5a1b5e7cb159"></a><a name="section-8.9"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.  Isolated cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported with sulfamethoxazole and trimethoprim, mainly in AIDS patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f602e2dd-b7c5-492b-9085-18d800d1e3d6"></a><a name="section-8.10"></a><p></p>
<h2>Respiratory</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> and pulmonary infiltrates (see <span class="Bold"><a href="#i4i_warnings_id_38a50f0c-09fe-4f1a-afa3-359fefa6c273">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c348485c-af8c-4351-a98b-c86784e731da"></a><a name="section-8.11"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Bold">Postmarketing Experience </span></p>
<p>The following adverse reactions have been identified during post-approval use of trimethoprim-sulfamethoxazole. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: </p>
<dl>
<dt></dt>
<dd>Σ Thrombotic <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenia purpura</span> </dd>
<dt></dt>
<dd>Σ <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c6e3a1bf-491f-4f57-87b9-526207d32ff2"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_411b0956-ad2f-4c4b-baa4-3d62a736cbbf"></a><a name="section-9.1"></a><p></p>
<h2>Acute</h2>
<p class="First">The amount of a single dose of sulfamethoxazole and trimethoprim that is either associated with symptoms of overdosage or is likely to be life-threatening has not been reported. Signs and symptoms of overdosage reported with sulfonamides include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> may be noted. <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> are potential late manifestations of overdosage.</p>
<p>Signs of acute overdosage with trimethoprim include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>.</p>
<p>General principles of treatment include the institution of gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, forcing oral fluids, and the administration of intravenous fluids if urine output is low and renal function is normal. Acidification of the urine will increase renal elimination of trimethoprim. The patient should be monitored with blood counts and appropriate blood chemistries, including electrolytes. If a significant <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs, specific therapy should be instituted for these complications. Peritoneal dialysis is not effective and hemodialysis is only moderately effective in eliminating sulfamethoxazole and trimethoprim.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_944900f3-7ddd-4a1c-8ffc-31122a16dad1"></a><a name="section-9.2"></a><p></p>
<h2>Chronic</h2>
<p class="First">Use of sulfamethoxazole and trimethoprim at high doses and/or for extended periods of time may cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> manifested as <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>. If signs of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> occur, the patient should be given leucovorin 5 to 15 mg daily until normal hematopoiesis is restored.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_64a68c49-9372-422c-ab0a-bb04ef9e09af"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Not recommended for use in pediatric patients less than 2 months of age.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d9f3a513-c791-47f2-bf91-3bb58be92926"></a><a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and Shigellosis in Adults and Pediatric Patients, and Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> in Children</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2b93ad6-4703-4716-9cf2-d15816b4429e"></a><a name="section-10.1.1"></a><p></p>
<h3>Adults</h3>
<p class="First">The usual adult dosage in the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> is four teaspoonfuls (20mL) Sulfamethoxazole and trimethoprim oral suspension every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e6ac4bd-30aa-4266-b139-569c185ccfa1"></a><a name="section-10.1.2"></a><p></p>
<h3>Children</h3>
<p class="First">The recommended dose for children with <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> or acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The following table is a guideline for the attainment of this dosage:</p>
<p>Children 2 months of age or older:</p>
<a name="id_61e91e22-f1f2-4f4e-90ea-ca60177c3062"></a><table width="0.000">
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" colspan="2" valign="top">Weight</td>
<td class="Botrule" align="center" colspan="2" valign="top">Dose - every 12 hours</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top">lb</td>
<td class="Botrule" align="center" valign="top">kg</td>
<td class="Botrule" align="center" colspan="2" valign="top">Teaspoonfuls</td>
</tr>
<tr>
<td align="center" valign="top">22</td>
<td align="center" valign="top">10</td>
<td align="center" colspan="2" valign="top">1 (5 mL)</td>
</tr>
<tr>
<td align="center" valign="top">44</td>
<td align="center" valign="top">20</td>
<td align="center" colspan="2" valign="top">2 (10 mL)</td>
</tr>
<tr>
<td align="center" valign="top">66</td>
<td align="center" valign="top">30</td>
<td align="center" colspan="2" valign="top">3 (15 mL)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">88</td>
<td class="Botrule" align="center" valign="top">40</td>
<td class="Botrule" align="center" colspan="2" valign="top">4 (20 mL)</td>
</tr>
</tbody>
</table>
<p><span class="Bold">For Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span>: When renal function is impaired, a reduced dosage should be employed using the following table:</p>
<a name="id_c74e4e3f-bd48-46ca-94d2-b8325d8d001d"></a><table width="0.000">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Creatinine Clearance (mL/min)</td>
<td class="Botrule" align="left" valign="top">Recommended Dosage Regimen</td>
</tr>
<tr>
<td align="center" valign="middle">Above 30</td>
<td align="center" valign="middle">Use standard regimen</td>
</tr>
<tr>
<td align="center" valign="middle">15 to 30</td>
<td align="center" valign="middle">½ the usual regimen</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle">Below 15</td>
<td class="Botrule" align="center" valign="middle">Use not recommended</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0fbfa761-75d1-4847-a6c4-d4a4d5884794"></a><a name="section-10.2"></a><p></p>
<h2>Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> in Adults</h2>
<p class="First">The usual adult dosage in the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> is four teaspoonfuls (20 mL) sulfamethoxazole and trimethoprim oral suspension every 12 hours for 14 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23f59512-7177-450e-b0c1-8cc09661d2c4"></a><a name="section-10.3"></a><p></p>
<h2>
<span class="Italics">Pneumocystis Carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_614a0c80-9f29-49dc-a4a8-201d49b15fa3"></a><a name="section-10.3.1"></a><p></p>
<h3>Treatment</h3>
<p class="First">Adults and Children: The recommended dosage for treatment of patients with documented <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis carinii pneumonia</span> is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">10</a> The following table is a guideline for the upper limit of this dosage:</p>
<a name="id_0a6453a5-dbf4-40b6-910e-c74006519734"></a><table width="0.000">
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" colspan="2" valign="top">Weight</td>
<td class="Botrule" align="center" colspan="2" valign="top">Dose - every 6 hours</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top">lb</td>
<td class="Botrule" align="center" valign="top">kg</td>
<td class="Botrule" align="center" colspan="2" valign="top">Teaspoonfuls</td>
</tr>
<tr>
<td align="center" valign="top">18</td>
<td align="center" valign="top">8</td>
<td align="center" colspan="2" valign="top">1 (5 mL)</td>
</tr>
<tr>
<td align="center" valign="top">35</td>
<td align="center" valign="top">16</td>
<td align="center" colspan="2" valign="top">2 (10 mL)</td>
</tr>
<tr>
<td align="center" valign="top">53</td>
<td align="center" valign="top">24</td>
<td align="center" colspan="2" valign="top">3 (15 mL)</td>
</tr>
<tr>
<td align="center" valign="top">70</td>
<td align="center" valign="top">32</td>
<td align="center" colspan="2" valign="top">4 (20 mL)</td>
</tr>
<tr>
<td align="center" valign="top">88</td>
<td align="center" valign="top">40</td>
<td align="center" colspan="2" valign="top">5 (25 mL)</td>
</tr>
<tr>
<td align="center" valign="top">106</td>
<td align="center" valign="top">48</td>
<td align="center" colspan="2" valign="top">6 (30 mL)</td>
</tr>
<tr>
<td align="center" valign="top">141</td>
<td align="center" valign="top">64</td>
<td align="center" colspan="2" valign="top">8 (40 mL)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">176</td>
<td class="Botrule" align="center" valign="top">80</td>
<td class="Botrule" align="center" colspan="2" valign="top">10 (50 mL)</td>
</tr>
</tbody>
</table>
<p>For the lower limit dose (75 mg/kg sulfamethoxazole and 15 mg/kg trimethoprim per 24 hours) administer 75% of the dose in the above table.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_678254b3-ecf9-49f6-bc8a-affda1c3e0d9"></a><a name="section-10.4"></a><p></p>
<h2>Prophylaxis</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e312acfe-4347-4ce5-b462-67fd0e269ba4"></a><a name="section-10.4.1"></a><p></p>
<h3>Adults</h3>
<p class="First">The recommended dosage for prophylaxis in adults is four teaspoonfuls (20 mL) of the oral suspension daily.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">11</a></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_48fe0484-2a43-4c33-9c9f-ab5b2ee602a1"></a><a name="section-10.4.2"></a><p></p>
<h3>Children</h3>
<p class="First">For children, the recommended dose is 750 mg/m<span class="Sup">2</span>/day sulfamethoxazole with 150 mg/m<span class="Sup">2</span>/day trimethoprim given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 1600 mg sulfamethoxazole and 320 mg trimethoprim.<a href="#i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1">12</a> The following table is a guideline for the attainment of this dosage in children:</p>
<a name="id_77d41122-f353-4b5e-aae3-a65567e8d309"></a><table width="0.000">
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="top">Body Surface Area</td>
<td class="Botrule" align="center" colspan="2" valign="top">Dose - every 12 hours</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top">(m<span class="Sup">2</span>)</td>
<td class="Botrule" align="center" colspan="2" valign="top">Teaspoonfuls</td>
</tr>
<tr>
<td align="center" valign="top">0.26</td>
<td align="center" colspan="2" valign="top">½ (2.5 mL)</td>
</tr>
<tr>
<td align="center" valign="top">0.53</td>
<td align="center" colspan="2" valign="top">1 (5 mL)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">1.06</td>
<td class="Botrule" align="center" colspan="2" valign="top">2 (10 mL)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d0da96d0-6d9b-4cfb-baf6-665777af1816"></a><a name="section-10.5"></a><p></p>
<h2>Travelers’ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> in Adults</h2>
<p class="First">For the treatment of travelers' <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, the usual adult dosage is four teaspoonfuls (20 mL) of sulfamethoxazole and trimethoprim oral suspension every 12 hours for 5 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_30353d0c-7302-4c1c-8771-a65fe328f1f2"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Sulfamethoxazole and Trimethoprim Oral Suspension USP, containing 200 mg sulfamethoxazole and 40 mg trimethoprim per teaspoonful (5 mL), is a cherry flavored suspension available in (473 mL) bottles.</p>
<p>Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Protect from light.</p>
<p>SHAKE WELL BEFORE USING.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact STI Pharma, LLC at 1-888-301-9680 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e829f083-5c6f-4ac1-a584-aa5f5a9142f1"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Kremers P, Duvivier J, Heusghem C. Pharmacokinetic Studies of Co-Trimoxazole in Man after Single and Repeated Doses. <span class="Italics">J Clin Pharmacol</span>. Feb-Mar 1974; 14:112–117.</li>
<li>Kaplan SA, et al. Pharmacokinetic Profile of Trimethoprim-Sulfamethoxazole in Man. <span class="Italics">J Infect Dis</span>. Nov 1973; 128 (Suppl): S547–S555.</li>
<li>Varoquaux O, et al. Pharmacokinetics of the trimethoprim-sulfamethoxazole combination in the elderly. <span class="Italics">Br J Clin Pharmacol</span>. 1985;20:575–581.</li>
<li>Rudoy RC, Nelson JD, Haltalin KC. <span class="Italics">Antimicrobial Agents Chemother</span>. May 1974;5:439–443.</li>
<li>National Committee for Clinical Laboratory Standards. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</span>; Approved Standard – Fourth Edition. NCCLS Document M7–A4, Vol.17, No. 2, NCCLS, Wayne, PA, January, 1997.</li>
<li>Hardy DW, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in patients with the <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span>. <span class="Italics">N Engl J Med</span>. 1992; 327: 1842–1848.</li>
<li>Marinella Mark A. 1999. Trimethoprim-induced <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>: An analysis of reported cases. <span class="Italics">Gerontol</span>. 45:209–212.</li>
<li>Margassery, S. and B. Bastani. 2002. Life threatening <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> secondary to trimethoprim-sulfamethoxazole treatment. <span class="Italics">J. Nephrol</span>. 14:410–414.</li>
<li>Brumfitt W, Pursell R. Trimethoprim/Sulfamethoxazole in the Treatment of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">Bacteriuria</span> in Women. <span class="Italics">J Infect Dis</span>. Nov 1973; 128 (Suppl):S657–S663.</li>
<li>Masur H. Prevention and treatment of <span class="Italics">Pneumocystis </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. <span class="Italics">N Engl J Med</span>. 1992; 327: 1853–1880.</li>
<li>Recommendations for prophylaxis against <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> for adults and adolescents infected with human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus. <span class="Italics">MMWR. </span>1992; 41(RR-4):1–11.</li>
<li>CDC Guidelines for prophylaxis against <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> for children infected with human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus. <span class="Italics">MMWR</span>. 1991; 40(RR-2):1–13.</li>
</ol>
<p class="First"></p>
<p>Manufactured for:</p>
<p><span class="Bold">STI PHARMA LLC</span></p>
<p>Langhorne, PA 19047</p>
<p></p>
<p>Rev. 02/13</p>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_8ebc6bca-15ad-4a9e-94f5-7dd14fb082d7"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Label Front Panel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3ef596c8-689e-4349-a5dc-11645f8332ef&amp;name=b848770a-figure-03.jpg"></div>
<div class="Figure"><img alt="Label Rear Panel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3ef596c8-689e-4349-a5dc-11645f8332ef&amp;name=b848770a-figure-04.jpg"></div>
<p class="First"><span class="Bold">SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION, USP</span></p>
<p><span class="Bold">200 mg/40 mg per 5 mL</span></p>
<p>Cherry Flavor</p>
<p><span class="Bold">Each teaspoonful (5 mL) contains:</span></p>
<p>Sulfamethoxazole.......................................200 mg</p>
<p>Trimethoprim..............................................40 mg</p>
<p>Alcohol........................................................0.26 %</p>
<p><span class="Bold">USUAL DOSAGE:</span> See package insert for dosage and full prescribing information. Dispense in a tight, light-resistant container as defined in the USP. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Protect from light.</p>
<p><span class="Bold">SHAKE WELL BEFORE USING.</span></p>
<p>Rx only</p>
<p><span class="Bold">16 fl oz (473 mL)</span></p>
<p>STI Pharma LLC</p>
<p>Langhorne, PA 19047</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULFATRIM 		
					</strong><br><span class="contentTableReg">sulfamethoxazole and trimethoprim suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54879-007</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SULFAMETHOXAZOLE</strong> (SULFAMETHOXAZOLE) </td>
<td class="formItem">SULFAMETHOXAZOLE</td>
<td class="formItem">200 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>TRIMETHOPRIM</strong> (TRIMETHOPRIM) </td>
<td class="formItem">TRIMETHOPRIM</td>
<td class="formItem">40 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIMETHICONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">red</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54879-007-16</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018615</td>
<td class="formItem">07/01/1983</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STI Pharma LLC
							(832714070)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>STI Pharma LLC (832714070)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>95ae9b0f-f4f9-499a-8e80-b05566d9048e</div>
<div>Set id: 3ef596c8-689e-4349-a5dc-11645f8332ef</div>
<div>Version: 3</div>
<div>Effective Time: 20131112</div>
</div>
</div> <div class="DistributorName">STI Pharma LLC</div></p>
</body></html>
